Angeles Medina
Overview
Explore the profile of Angeles Medina including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
64
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Medina A, Muntanola A, Crespo M, Ramirez A, Hernandez-Rivas J, Abrisqueta P, et al.
Med Clin (Barc)
. 2025 Jan;
PMID: 39799061
Introduction: Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in adults in Western countries, with a median age at diagnosis of 72 years. This guide, developed by...
2.
Chatzikonstantinou T, Scarfo L, Karakatsoulis G, Minga E, Chamou D, Iacoboni G, et al.
EClinicalMedicine
. 2023 Nov;
65:102307.
PMID: 38033506
Background: Patients with chronic lymphocytic leukemia (CLL) have a higher risk of developing other malignancies (OMs) compared to the general population. However, the impact of CLL-related risk factors and CLL-directed...
3.
Montanes B, Casado G, Medina A, Nieto P, Ramirez-Payer A
Farm Hosp
. 2022 Apr;
46(2):72-79.
PMID: 35379098
Objective: Chronic lymphocytic leukaemia places a considerable economic burden on the Spanish National Health System. This study estimated the direct costs of chronic lymphocytic leukaemia oral targeted therapies from 2011...
4.
Galvez-Carvajal L, Quero C, Casanova M, Diaz C, Chicharo J, Espeso M, et al.
Int J Hematol
. 2021 Sep;
115(1):54-60.
PMID: 34546542
Up to 25% of patients with classical Hodgkin lymphoma (cHL) and a negative interim PET/CT will progress. Unfortunately, there are few published studies on the predictive value of PET/CT performed...
5.
Abrisqueta P, Loscertales J, Terol M, Ramirez Payer A, Ortiz M, Perez I, et al.
Clin Lymphoma Myeloma Leuk
. 2021 Sep;
21(12):e985-e999.
PMID: 34511320
Background: Ibrutinib demonstrated remarkable efficacy and favorable tolerability in patients with untreated or relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including those with high-risk genetic alterations. The IBRORS-CLL study assessed the...
6.
Abrisqueta P, Delgado J, Alcoceba M, Oliveira A, Loscertales J, Hernandez-Rivas J, et al.
Br J Haematol
. 2020 Jun;
190(6):854-863.
PMID: 32519351
Richter syndrome (RS) is an uncommon evolution of chronic lymphocytic leukaemia (CLL) with a dismal prognosis. Clinical-biological features predicting outcome and best therapeutic approach for these patients remain to be...
7.
Xicoy B, Germing U, Jimenez M, Garcia O, Garcia R, Schemenau J, et al.
Eur J Haematol
. 2015 Sep;
97(1):33-8.
PMID: 26341961
Background: The efficacy of erythropoietic-stimulating agents (ESA) in chronic myelomonocytic leukemia (CMML) is unknown. Our objective was to analyze erythroid response (ER) and overall survival (OS) in a series of...
8.
Garcia-Delgado R, de Miguel D, Bailen A, Gonzalez J, Bargay J, Falantes J, et al.
Leuk Res
. 2014 May;
38(7):744-50.
PMID: 24795069
We investigated the effectiveness and tolerability of azacitidine in patients with World Health Organization-defined myelodysplastic syndromes, or acute myeloid leukemia with 20-30% bone marrow blasts. Patients were treated with azacitidine,...
9.
Sanchez-Gonzalez B, Penalver F, Medina A, Guillen H, Calleja M, Gironella M, et al.
Leuk Res
. 2011 Dec;
36(6):709-14.
PMID: 22154023
Bendamustine is a alkylating agent with a purine-like benzamidazole ring currently approved in Europe for indolent non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and multiple myeloma. Our aim was to...